New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
10:06 EDTAGN, VRXValeant sees FY15 cash EPS about $9.90 with deals, $9.40 with debt repayment
Valeant (VRX) sees FY15 cash EPS about $9.90 with deals, $9.40 with debt repayment. Valeant sees FY15 revenue about $9.7B with deals, $8.9B with debt repayment. Valeant laid out two alternate scenarios for its standalone projections, namely a debt repayment case and an acquisition case. Under the debt repayment scenario, leverage decreases to 2.9x in 2015 and 1.9x in 2016. Under the acquisition case, the company assumes acquisition of about $5B in 2015 and about $10B in 2016.
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use